Joseph M. Custodio
- Virology top 0.5%
- HIV Research and Treatment 15
- Infectious Diseases top 1%
- HIV/AIDS drug development and treatment 26
- HIV/AIDS Research and Interventions 5
- Emergency Medicine top 1%
- HIV-related health complications and treatments 9
- Pharmaceutical Science top 5%
- Hepatology top 5%
-
- Pharmacological Effects and Toxicity Studies 12
-
- Drug Transport and Resistance Mechanisms 3
- Cancer Treatment and Pharmacology 3
-
- Pharmacogenetics and Drug Metabolism 3
Joseph M. Custodio
40 papers receiving 2.0k citations
Hit Papers
Peers
Comparison fields: 5 of 100
- Virology 874
- Infectious Diseases 1.4k
- Emergency Medicine 556
- Pharmaceutical Science 123
- Hepatology 135
Countries citing papers authored by Joseph M. Custodio
This map shows the geographic impact of Joseph M. Custodio's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joseph M. Custodio with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joseph M. Custodio more than expected).
Fields of papers citing papers by Joseph M. Custodio
This network shows the impact of papers produced by Joseph M. Custodio. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joseph M. Custodio. The network helps show where Joseph M. Custodio may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Joseph M. Custodio, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2023 | 16 | |
| 2 | 2023 | 3 | |
| 3 | 2022 | 20 | |
| 4 | 2022 | 3 | |
| 5 | 2018 | 37 | |
| 6 | 2018 | 30 | |
| 7 | 2018 | 117 | |
| 8 | Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380–1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trialbreakdown → | 2017 | 278 |
| 9 | Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trialbreakdown → | 2017 | 257 |
| 10 | 2017 | 10 | |
| 11 | 2016 | 10 | |
| 12 | 2015 | 158 | |
| 13 | 2015 | 121 | |
| 14 | 2015 | 5 | |
| 15 | 2014 | 12 | |
| 16 | 2013 | 14 | |
| 17 | 2013 | 30 | |
| 18 | 2007 | 313 | |
| 19 | 2005 | 34 | |
| 20 | 2002 | 72 |
About Joseph M. Custodio
Joseph M. Custodio is a scholar working on Virology, Infectious Diseases and Emergency Medicine, having authored 40 papers that have together received 2.0k indexed citations. Recurring topics across this work include HIV/AIDS drug development and treatment (26 papers), HIV Research and Treatment (15 papers), Pharmacological Effects and Toxicity Studies (12 papers), HIV-related health complications and treatments (9 papers), HIV/AIDS Research and Interventions (5 papers), Drug Transport and Resistance Mechanisms (3 papers), Pharmacogenetics and Drug Metabolism (3 papers) and Cancer Treatment and Pharmacology (3 papers). The work is most often cited by research in Virology (874 citations), Infectious Diseases (1.4k citations) and Emergency Medicine (556 citations). Joseph M. Custodio has collaborated with scholars based in United States, United Kingdom and Spain. Frequent co-authors include Leslie Z. Benet, Chi‐Yuan Wu, Andrew Cheng, Erin Quirk, Hal Martin, Kirsten White, Brian P. Kearney, Anthony Mills, Marshall W. Fordyce and Gordon Crofoot. Their work appears in journals such as The Lancet, Journal of Clinical Oncology and Molecular and Cellular Biology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.